How a $2.80 Play Turned Into Nearly $500k Nest Egg

Hey there, bargain hunter. Rocket Lab reports Q3 2026 results tonight, after the close, and the consensus sitting at roughly $257 million in revenue sounds like a layup for a company that has beaten its own guidance top line in back-to-back quarters. It is not quite that simple.

Scoreboard

Revenue grew 63.5% year-over-year in Q1 to $200 million, then 62% in Q2 to $234 million. The backlog hit $2.36 billion exiting June, up 137% from a year earlier, with 90-plus launches contracted. The stock has fallen roughly 24% year-to-date heading into tonight, and it closed at $53.07 on November 6. The business keeps growing. The stock keeps sliding. Something is being priced in.

The Real Reason

That something is margin compression. Rocket Lab itself guided Q3 GAAP gross margins at 29% to 31%, well below the 36.1% posted in Q2 and the 38.2% record set in Q1. Integration and mix issues are absorbing operating leverage faster than revenue can outrun them. On Rocket Lab’s Q2 update, management pointed to weaker mix in several product lines as a driver of the Q3 gross margin guide. The backlog looks like a moat. The income statement looks like a construction site.

Deep Dive

Rocket Lab earns money two ways: launch services through Electron and the hypersonic HASTE program, and space systems through satellite components, structures, and power systems. Space systems represents about 60% of backlog by value. That segment can carry higher upfront costs but better long-run margins once programs reach production scale. The government is a heavy customer, with a single government customer accounting for 42% of first-half 2026 revenue.

On the contract front, the Space Force awards that landed in the Q2 time frame were big: a $266 million contract for suborbital launches and a $397 million award to build and launch “Flatellites” for the Space Force’s SB-AMTI program, $663 million combined. These are the kinds of wins that inflate backlog and keep the revenue engine fed.

Neutron, the medium-lift reusable rocket meant to unlock a much bigger addressable market, slipped again. Rocket Lab said in mid-October that Neutron’s inaugural launch is now expected in 2027 after a manufacturing defect was identified in carbon composite structures, and the fix expanded the company’s test program. The delay is real, but signed Neutron contracts already sit inside the $2.36 billion backlog, with customers choosing multi-launch partnerships despite the schedule uncertainty.

Is It Cheap?

At roughly $53 a share, RKLB is not a value stock by any definition. What it is: a business that just put up 60% plus year-over-year growth for two straight quarters, with a backlog where about 45% is expected to convert into revenue within 12 months. The Iridium acquisition, a deal with an implied enterprise value of about $8.0 billion, pairs Rocket Lab’s manufacturing with Iridium’s global satellite communications network and rare spectrum assets, and Rocket Lab has said it expects the transaction to close in mid-2027, pending approvals. Iridium also reported roughly 2.7 million billable subscribers as of September 30, 2026. That is the optionality baked into the multiple.

Bull / Base / Bear

• Bull: Q3 beats guidance, margins recover toward 35% by Q4, Neutron launches commercially in 2027, Iridium closes on schedule and adds free cash flow.
• Base: Revenue hits $257 million tonight, margins stay soft through Q4 acquisition integration and product mix, Neutron flies in 2027 but cadence ramps slowly.
• Bear: Margin guidance misses further, Iridium regulatory approval drags, Neutron faces another delay, and the $1.944 billion ATM equity raise used to finance the Iridium deal keeps a lid on the stock.

Action Plan

Tonight’s number to watch is not revenue. It is the Q4 gross margin guide. If Rocket Lab signals a path back toward 35% plus GAAP margins, the selloff since October looks like an overreaction to a manufacturing setback and messy mix. If margins stay compressed into 2027, the premium multiple becomes harder to hold. Scale in only on confirmed margin recovery, not on the backlog headline alone.

Cheap Investor Checklist

• Q3 revenue vs. $257 million consensus
• Q4 GAAP gross margin guidance: watch for recovery above 33%
• Backlog composition: launch vs. space systems split
• Neutron revised timeline and new launch date specificity
• Iridium deal regulatory progress and financing cost updates
• Government revenue concentration: does the 42% figure hold or expand?
• Adjusted EBITDA loss trajectory toward breakeven

Bottom Line

If margins recover and Neutron gets a firm 2027 launch window tonight, RKLB near the low-to-mid $50s is paying a reasonable price for a space-infrastructure compounder with real contracted revenue. If the margin guide disappoints again, the backlog is not enough insulation. This one hinges on the Q4 outlook, not the Q3 headline.